Introduction
Lennox-Gastaut syndrome (LGS) is a well-defined epileptic encephalopathy highly drug resistant. The first-line treatment option is valproate (VPA), usually in combination with lamotrigine.
1,2 VPA has been linked to serious hepatotoxicity. It is rare, typically idiosyncratic but it is recommended to avoid its utilization in patient with pre-existing liver disease, in patients with personal or family history of metabolic diseases implying beta-oxydation, mithocondrial and peroxisomal functions. 3, 4 Careful monitoring should be provided when VPA is prescribed in children under the age of 2 years, in association with enzymeinducing drugs, neurometabolic diseases or hereditary metabolic disorders. 3, 4 In these situations, administration of VPA should be done after careful evaluation of the risk/benefit ratio. We present a liver transplanted patient with LGS successfully treated with VPA.
Case report
The history of this patient begins at the age of 2 months when she presented severe hepatic failure. The diagnostic of congenital biliary atresia was made and she was immediately submitted to a hepatoportoenterostomy. This failed and one year later she had a first liver transplant. Unfortunately, it was rejected and the child fell in hepatic coma. In November 1989, at age 2 years, she received her second transplant and was put on immunosuppressive medications. She rapidly developed chronic renal insufficiency, arterial hypertension. Epilepsy appeared in September 1990, at the age of 3 years, with two episodes of absence status. Her first EEGs were normal and she was treated with intermittent benzodiazepines. Generalized tonic-clonic seizures (GTCS), tonic seizures, and atypical absences appeared with increasing frequency. She could present multiple traumatic drop attacks per day, often causing surgical intervention. Her behavior became hyperactive and her learning abilities declined significantly. The EEGs showed diffuse slow spikes with polyspikes-waves and fast rhythms during sleep. MRI demonstrated a diffuse nonspecific cerebral atrophy. Clonazepam, clobazam, lamotrigine, levetiracetam, phenobarbital, ethosuximide, topiramate, ACTH (tetracosactide) and hydrocortisone were successively tried (Table 1) , always under strict control of renal and hepatic functions. The epilepsy nevertheless remained intractable. In June 2009, at age 22.5 years, video-EEG monitoring during 48 h showed slow background activity fragmented by multiple generalized slow spike-waves and polyspike-waves, and many subtle tonic seizures (Fig. 1) , as well as enhanced epileptic abnormality and prolonged discharges of fast activity during sleep. A diagnosis of LGS was proposed and after a comprehensive discussion with the patient's nephrologists and hepato-gastro-enterologist, VPA was started. It was titrated very carefully with 100 mg weekly increments up to 1000 mg/d (blood level 55.6 mg/l). The baseline therapy included phenobarbital (100 mg/d; blood level: 36 mg/l), lamotrigine (125 mg/d; blood level: 4.81 mg/l) and topiramate (175 mg/d), as well as immunosuppressive, antiviral, anti-anemic, hypo-phosphoric and alkaline medication. The first four months, hepatic and renal functions were controlled every week, after that every month. The values of transaminases were in reference ranges: aspartate transaminase between 18 and 44 U/l (<46 U/l) and alanine transaminase between 16 and 50 (<52 U/l). On VPA 1000 mg/d, the seizure frequency decreased significantly. Taking into consideration good tolerability and normal liver function, we decreased phenobarbital to 50 mg/d and increased VPA to 1500 mg/d (Table 1) . At this dose the daily drop attacks and GTCS totally ceased, with only some tonic seizures persisting around awakening.
Discussion
A minor increase in serum aminotransferases is observed in 30-50% of patients treated with VPA. It appears to be dose related, transient and is observed more commonly during initial therapy and in patients comedicated with phenobarbital or phenytoin. 5 When this increase remains moderate, lower than two to three times baseline values, asymptomatic, and without any abnormal changes in other liver function test results, the treatment may be continued. VPA is a treatment of choice in LGS especially in association with lamotrigine. During many years, VPA was avoided in this patient because of its potential hepatotoxicity. However the good functioning of the transplanted liver permitted its introduction. This patient had significant seizure reduction, without falls, and her quality of life was dramatically improved. VPA was used safely in a liver transplanted patient under the strict control of the hepatic function. 
